Clinical trials

10

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Exploratively Evaluate the Safety, Tolerability and Pharmacokinetics of DA-5223 Compared With DA-5223-R in Healthy Adult Subjects

This study will exploratively evaluate the safety, tolerability and pharmacokinetics of DA-5223 compared with DA-5223-R in healthy adult subjects

Participants needed: 12
Trial details
Phase: Phase 1Age: 19-55Biological sex: AllType: InterventionalSponsor: Dong-A ST Co., Ltd.Updated: Jun 8, 2026Locations: 1
Eligibility criteria

Adult male or female, 19 years to 55 years [+2]

The subjects with acute illness [+4]

Status: Recruiting

A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

The goal of this clinical trial is to determine the MTD or OBED of DA-3501 given in Q3W to determine a wRP2D in patients with advanced CLDN18.2 expressing (CLDN18.2+) GC/GEJ and advanced CLDN18.2+ PDAC. Participants will receive the assigned dose once every three weeks and, according to the study procedures, will undergo tumor assessments as well as safety assessments, PK evaluations, and ADA testing.

Participants needed: 51
Trial details
Phase: Phase 1Age: 19+Biological sex: AllType: InterventionalSponsor: Dong-A ST Co., Ltd.Updated: May 20, 2026Locations: 3
Eligibility criteria

Patients aged ≥ 19 years [+3]

Cardiac abnormalities [+3]

Status: Not yet recruiting

A Study to Evaluate the Bioequivalence of DA-5230 Compared to DA-5230-R

A study to evaluate the bioequivalence of DA-5230 compared to DA-5230-R

Participants needed: 60
Trial details
Phase: Phase 1Age: 19-55Biological sex: AllType: InterventionalSponsor: Dong-A ST Co., Ltd.Updated: Apr 7, 2026
Eligibility criteria

Healthy participants aged 19 to 55 years at the time of screening visit [+1]

Participants who have received an investigational product in another clinical tr... [+1]

Status: Not yet recruiting

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

This study is a multicenter, double-blind, active-controlled, randomized, parallel clinical trial to evaluate the efficacy and safety of DA-2811 when added to ongoing BT-1 and BT-2 combination therapy in patients with type 2 diabetes who have inadequate glycemic control

Participants needed: 288
Trial details
Phase: Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: Dong-A ST Co., Ltd.Updated: Nov 20, 2025Locations: 1
Eligibility criteria

Patients with type II diabetes mellitus aged 19 years or older [+3]

Patients with type 1 diabetes, secondary diabetes, gestational diabetes, diabeti... [+4]

Status: Not yet recruiting

Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes

This study is a multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of DA-5218 in patients with type 2 diabetes who have inadequate glycemic control with metformin

Participants needed: 238
Trial details
Phase: Phase 4Age: 19+Biological sex: AllType: InterventionalSponsor: Dong-A ST Co., Ltd.Updated: Nov 17, 2025
Eligibility criteria

7.0%≤HbA1c≤10.5% and fasting glucose≤270mg/dL [+1]

Type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes me... [+3]

Status: Not yet recruiting

Clinical Trial of Comparing DA-5222 Single-administration and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects

This study is to compare pharmacokinetics and safety profiles of DA-5222 single-administration and co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in healthy adult subjects

Participants needed: 48
Trial details
Phase: Phase 1Age: 19+Biological sex: AllType: InterventionalSponsor: Dong-A ST Co., Ltd.Updated: Jun 6, 2025Locations: 1
Eligibility criteria

Healthy volunteers [+3]

Subjects with clinically significant medical history [+2]

Status: Not yet recruiting

To Evaluate Effect of Food of DA-5222 in Healthy Adult Subjects

This study is to evaluate the effect of food on pharmacokinetics of DA-5222 in healthy adult subjects

Participants needed: 32
Trial details
Phase: Phase 1Age: 19+Biological sex: AllType: InterventionalSponsor: Dong-A ST Co., Ltd.Updated: May 28, 2025Locations: 1
Eligibility criteria

Healthy volunteers [+3]

Subjects with clinically significant medical history [+2]

Status: Recruiting

Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

This study is an Open-Label, Phase 1/2a, First-in-Human, Dose-Escalation, Dose-Expansion, and Proof-of-Concept Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors.

Participants needed: 125
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Dong-A ST Co., Ltd.Updated: Feb 12, 2025Locations: 2
Eligibility criteria

Aged 18 and older. [+7]

Inability to take oral medications or gastrointestinal abnormalities potentially... [+9]

Status: Not yet recruiting

Pharmacokinetics and Safety Profiles After Administration of DA-5221_01 and Co-administration of 5221_01-R1 and DA-5221_01-R2 in Healthy Adult Volunteers

Pharmacokinetics and Safety Profiles After Administration of DA-5221\_01 and Co-administration of 5221\_01-R1 and DA-5221\_01-R2 in Healthy Adult Volunteers

Participants needed: 44
Trial details
Phase: Phase 1Age: 19+Biological sex: AllType: InterventionalSponsor: Dong-A ST Co., Ltd.Updated: Sep 27, 2024Locations: 1
Eligibility criteria

Healthy volunteers [+3]

Subjects with clinically significant medical history [+1]

Status: Recruiting

Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature

This study evaluates long-term safety and effectiveness of Growtropin®-II treatment in children with short stature.

Participants needed: 2,500
Trial details
Age: 2+Biological sex: AllType: ObservationalSponsor: Dong-A ST Co., Ltd.Updated: Apr 12, 2023Locations: 1Duration: 10 Years
Eligibility criteria

Children with short stature by growth hormone deficiency(GHD) or idiopathic shor... [+1]

Children with Epiphyseal closure